DE60335292D1 - 4-METHYLHEXANOIC KAHALALIDE F COMPOUND - Google Patents

4-METHYLHEXANOIC KAHALALIDE F COMPOUND

Info

Publication number
DE60335292D1
DE60335292D1 DE60335292T DE60335292T DE60335292D1 DE 60335292 D1 DE60335292 D1 DE 60335292D1 DE 60335292 T DE60335292 T DE 60335292T DE 60335292 T DE60335292 T DE 60335292T DE 60335292 D1 DE60335292 D1 DE 60335292D1
Authority
DE
Germany
Prior art keywords
kahalalide
methylhexanoic
compound
antitumoral
antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335292T
Other languages
German (de)
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Manuel Aviles
Marchante Maria Del Carmen Cuevas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmamar SA
Original Assignee
Pharmamar SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharmamar SA filed Critical Pharmamar SA
Priority claimed from PCT/US2003/033207 external-priority patent/WO2004035613A2/en
Application granted granted Critical
Publication of DE60335292D1 publication Critical patent/DE60335292D1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.
DE60335292T 2002-10-18 2003-10-20 4-METHYLHEXANOIC KAHALALIDE F COMPOUND Expired - Lifetime DE60335292D1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds
PCT/US2003/033207 WO2004035613A2 (en) 2002-10-18 2003-10-20 4-methylhexanoic kahalaide f compound

Publications (1)

Publication Number Publication Date
DE60335292D1 true DE60335292D1 (en) 2011-01-20

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335292T Expired - Lifetime DE60335292D1 (en) 2002-10-18 2003-10-20 4-METHYLHEXANOIC KAHALALIDE F COMPOUND

Country Status (12)

Country Link
KR (2) KR20110114690A (en)
AT (1) ATE490975T1 (en)
AU (1) AU2003285911B2 (en)
CY (1) CY1111319T1 (en)
DE (1) DE60335292D1 (en)
DK (1) DK1572726T3 (en)
HK (1) HK1082261A1 (en)
IL (1) IL167724A (en)
NO (1) NO333448B1 (en)
PL (1) PL209129B1 (en)
PT (1) PT1572726E (en)
SI (1) SI1572726T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
WO2002036145A2 (en) * 2000-10-31 2002-05-10 Pharma Mar, S.A. Kahalalide f formulation
WO2003033012A1 (en) * 2001-10-19 2003-04-24 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
KR20110114690A (en) 2011-10-19
AU2003285911B2 (en) 2009-11-19
PL209129B1 (en) 2011-07-29
HK1082261A1 (en) 2006-06-02
NO20052379L (en) 2005-07-15
NO20052379D0 (en) 2005-05-13
CY1111319T1 (en) 2015-08-05
KR101149095B1 (en) 2012-05-30
NO333448B1 (en) 2013-06-10
SI1572726T1 (en) 2011-04-29
KR20050070056A (en) 2005-07-05
IL167724A (en) 2012-01-31
DK1572726T3 (en) 2011-03-28
PL377056A1 (en) 2006-01-23
ATE490975T1 (en) 2010-12-15
PT1572726E (en) 2011-02-14
AU2003285911A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
CY1112743T1 (en) STEERIFIOMETRICULARLY enriched 3-Aminocarbonyl bicyclic pyrimidinodiamine compounds and their uses
EA200400971A1 (en) Fluorine-substituted cycloalkanoylindoles, compositions containing such compounds, and methods of treatment
BRPI0418251A (en) phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
EA200500392A1 (en) PYRIMIDINE DERIVATIVES AND THEIR APPLICATION AS CB2 MODULATORS
BG66084B1 (en) Cyclopentanoindoles, compositions containing such compounds and their use
BR0211390A (en) Treatment of nail infections with at
CY1108146T1 (en) Beta-Amino-Heterocyclic-Dipeptidyl Peptide Suspensions for the Treatment or Prevention of Diabetes
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
EA200602221A1 (en) NEW APPLICATION OF PEPTIDE CONNECTIONS FOR THE TREATMENT OF PAIN IN TRIGEMINAL NEURALGIA
BG66080B1 (en) Substituted thioacetamides
MXPA04003796A (en) Substituted thioacetamides.
ATE510822T1 (en) POTASSIUM CHANNEL INHIBITORS
ATE486915T1 (en) AZEOTROP-LIKE COMPOSITION OF 1,2-DICHLORO-3,3,3-TRIFLUOROPROPENE AND HYDROGEN FLUORIDE
ATE549024T1 (en) QUINAZOLINE POTASSIUM CHANNEL INHIBITORS
SE9901077D0 (en) Novel use
MXPA05004133A (en) 4-methylhexanoic kahalaide f compound.
MXPA02011039A (en) Fungicidal combinations of active agents.
EP1667976A4 (en) Isoquinolinone potassium channel inhibitors
ATE372330T1 (en) N-SULFONYLUREA APOPTOSIS PROMOTER
DE60213802D1 (en) CAK INHIBITORS AND ITS USES
BR0115139A (en) Bisheterocyclic compounds with antitumor and chemosensitizing activity
CY1111319T1 (en) 4-Methyl-hexanoic acid compound F
BR0312183A (en) Use of benziselenazolone compounds against ischemic myocardial injury
ES2194744T3 (en) DERIVATIVES OF QUINOCARDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION AS ANTIFUNGICOS.
TW200607493A (en) Potassium channel inhibitors